Abstract:Purpose: To evaluate the potential utility of histone deacetylase inhibitors (HDACi) for treatment of retinoblastoma (RB). Experimental design: Growth-inhibitory effects of HDACi [trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), or MS-275] were assessed in human and transgenic murine RB cells. Effects of TSA and MS-275 were also assessed in combination with standard therapeutic agents for RB. Proapoptotic effects of MS-275 and TSA were evaluated by caspase-3/7 activity, Annexin V translocation, and/or Bim expression analyses. Effects of MS-275 on cell cycle distribution and reactive oxygen species levels were determined by flow cytometry. Retinal tissue morphology was evaluated in mice after local administration of MS-275. Analysis of retinal acetyl-histone levels was used to assess MS-275 delivery after systemic administration. Therapeutic effects of MS-275 were determined in transgenic mouse and rat ocular xenograft models of RB after i.p. injection of 20 mg/kg every other day for 21 or 13 days, respectively. Results: TSA, SAHA, and MS-275 dose dependently reduced RB cell survival. TSA and MS-275 showed additive growth-inhibitory effects in combination with carboplatin, etoposide, or vincristine. TSA and MS-275 increased caspase-3/7 activity. MS-275 increased Annexin V membrane translocation and induced G1 arrest. Cytotoxicity of MS-275 was dependent on increased reactive oxygen species levels and was reversed by antioxidant pretreatment. Intraocular administration of 1 microL of 10 micromol/L MS-275 did not alter ocular tissue morphology. Increased acetyl-histone levels confirmed MS-275 delivery to retinal tissue after systemic administration. MS-275 significantly reduced tumor burden in both mouse and rat models of RB. Conclusions: HDACi should be considered for clinical trials in children with RB.

Histone Deacetylases in Retinoblastoma

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma

Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma

Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma

Histone deacetylases and cancer: causes and therapies

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells

The application of histone deacetylases inhibitors in glioblastoma

Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

Technologies of Targeting Histone Deacetylase in Drug Discovery: Current Progress and Emerging Prospects.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Targeting histone deacetylases: Emerging applications beyond cancer

Targeting histone deacetylases for cancer therapy: Trends and challenges

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor

Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics.

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer